scPharmaceuticals (NASDAQ:SCPH) Earns Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of scPharmaceuticals (NASDAQ:SCPH) in a research report sent to investors on Monday, Benzinga reports. They currently have a $18.00 target price on the stock. HC Wainwright also issued estimates for scPharmaceuticals’ Q3 2024 earnings at ($0.28) EPS, Q4 2024 earnings at ($0.25) EPS, FY2024 earnings at ($1.33) EPS, Q1 2025 earnings at $0.17 EPS, Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.66) EPS, FY2026 earnings at $0.10 EPS, FY2027 earnings at $1.03 EPS and FY2028 earnings at $2.02 EPS.

scPharmaceuticals Stock Up 5.7 %

Shares of scPharmaceuticals stock opened at $5.39 on Monday. The business’s fifty day moving average price is $4.53 and its two-hundred day moving average price is $4.77. The company has a debt-to-equity ratio of 4.32, a current ratio of 4.84 and a quick ratio of 3.66. The company has a market capitalization of $269.66 million, a P/E ratio of -3.64 and a beta of 0.11. scPharmaceuticals has a 1-year low of $3.24 and a 1-year high of $8.05.

Institutional Trading of scPharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Thomasville National Bank raised its stake in shares of scPharmaceuticals by 11.5% in the 1st quarter. Thomasville National Bank now owns 36,800 shares of the company’s stock worth $185,000 after buying an additional 3,800 shares in the last quarter. Balanced Rock Investment Advisors LLC grew its holdings in shares of scPharmaceuticals by 9.2% during the first quarter. Balanced Rock Investment Advisors LLC now owns 57,248 shares of the company’s stock valued at $287,000 after buying an additional 4,827 shares in the last quarter. Raymond James & Associates grew its holdings in shares of scPharmaceuticals by 6.6% during the fourth quarter. Raymond James & Associates now owns 87,049 shares of the company’s stock valued at $546,000 after buying an additional 5,377 shares in the last quarter. Perkins Capital Management Inc. purchased a new position in shares of scPharmaceuticals during the first quarter valued at $53,000. Finally, Bank of New York Mellon Corp grew its stake in scPharmaceuticals by 15.1% in the second quarter. Bank of New York Mellon Corp now owns 86,101 shares of the company’s stock valued at $375,000 after purchasing an additional 11,269 shares in the last quarter. Institutional investors own 89.52% of the company’s stock.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.